PL406517A1 - Application of kynurenic acid and its salts and pharmaceutical composition - Google Patents

Application of kynurenic acid and its salts and pharmaceutical composition

Info

Publication number
PL406517A1
PL406517A1 PL406517A PL40651713A PL406517A1 PL 406517 A1 PL406517 A1 PL 406517A1 PL 406517 A PL406517 A PL 406517A PL 40651713 A PL40651713 A PL 40651713A PL 406517 A1 PL406517 A1 PL 406517A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
salts
application
kynurenic acid
acid
Prior art date
Application number
PL406517A
Other languages
Polish (pl)
Other versions
PL226845B1 (en
Inventor
Waldemar Turski
Izabela Natalia Zakrocka
Janusz Sadowski
Elżbieta Kompanowska-Jezierska
Bożena Bądzyńska
Original Assignee
Uniwersytet Medyczny W Lublinie
Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie, Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan filed Critical Uniwersytet Medyczny W Lublinie
Priority to PL406517A priority Critical patent/PL226845B1/en
Publication of PL406517A1 publication Critical patent/PL406517A1/en
Publication of PL226845B1 publication Critical patent/PL226845B1/en

Links

Abstract

Przedmiotem wynalazku jest zastosowanie medyczne kwasu kynureninowego o wzorze ogólnym 1, który wykazuje działanie sodopędne oraz moczopędne, do wytwarzania leku do leczenia zaburzeń gospodarki wodno-elektrolitowej organizmu, a zwłaszcza do leczenia i profilaktyki w zakresie chorób przebiegających z nadmiernym gromadzeniem się płynów w tkankach. Przedmiotem wynalazku jest także kompozycja farmaceutyczna zawierająca kwas kynurenionowy.The subject of the invention is the medical use of kynurenine acid of general formula 1, which has a diuretic and diuretic effect, for the preparation of a medicament for the treatment of disorders of the body's water and electrolyte balance, in particular for the treatment and prevention of diseases involving excessive accumulation of fluid in tissues. The invention also relates to a pharmaceutical composition comprising kynureionic acid.

PL406517A 2013-12-13 2013-12-13 Application of kynurenic acid and its salts and pharmaceutical composition PL226845B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL406517A PL226845B1 (en) 2013-12-13 2013-12-13 Application of kynurenic acid and its salts and pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406517A PL226845B1 (en) 2013-12-13 2013-12-13 Application of kynurenic acid and its salts and pharmaceutical composition

Publications (2)

Publication Number Publication Date
PL406517A1 true PL406517A1 (en) 2015-06-22
PL226845B1 PL226845B1 (en) 2017-09-29

Family

ID=53396737

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406517A PL226845B1 (en) 2013-12-13 2013-12-13 Application of kynurenic acid and its salts and pharmaceutical composition

Country Status (1)

Country Link
PL (1) PL226845B1 (en)

Also Published As

Publication number Publication date
PL226845B1 (en) 2017-09-29

Similar Documents

Publication Publication Date Title
BR112015001419A8 (en) compound, pharmaceutical composition, and use of a compound or a pharmaceutically acceptable salt thereof
TR201904614T4 (en) Novel pyrazole derivative.
TR201904455T4 (en) 1,2,4-triazoles and their uses as nuclear transport modulators.
BR112015029512A2 (en) pyrazolopyrrolidine derivatives and their use in the treatment of diseases
ME02414B (en) Treatment of crohn's disease with laquinimod
HRP20171648T1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
PH12016502355A1 (en) Pharmaceutical composition
TR201818927T4 (en) Improvement in Catheters
BR112015012197A8 (en) cdk mtor inhibitor uses, and pharmaceutical combination comprising the same
BR112014008789A2 (en) prevention and treatment of eye conditions
BR112013015855A2 (en) compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications; and, pharmaceutical composition.
BR112015007814A2 (en) diagnosis, prevention and treatment of joint disease
BR112015007366A2 (en) acylaminopyrimidine derivatives for the treatment of viral infections and other diseases
BR112015001158A2 (en) ophthalmic formulation and its use and method for improving, reducing or treating presbyopia
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
PH12016502352A1 (en) Pharmaceutical composition
AR089862A1 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
TW201613578A (en) Pharmaceutical combinations
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
BR112016029067A2 (en) "compound, pharmaceutical composition, and methods for inhibiting the renal external medullary potassium channel, for causing diuresis, natriuresis or both and for treating one or more disorders".
BR112015022982A2 (en) macrocyclic rip2 kinase inhibitors
EA201600318A1 (en) CYCLIC TIENOURACILCARBOXAMIDES AND THEIR APPLICATION
BR112015027992A2 (en) Use of Petroselinic Acid to Combat Body Figure Aesthetic Disorders
FR2961695B1 (en) USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use